Next Article in Journal
Palladacyclic Conjugate Group Promotes Hybridization of Short Oligonucleotides
Next Article in Special Issue
Sepsis: Precision-Based Medicine for Pregnancy and the Puerperium
Previous Article in Journal
DNA Damage-Response Pathway Heterogeneity of Human Lung Cancer A549 and H1299 Cells Determines Sensitivity to 8-Chloro-Adenosine
Previous Article in Special Issue
Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment
Open AccessArticle

Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers

Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan; #2 Yude Road, Taichung 40447, Taiwan
Division of General Pediatrics, China Medical University Children’s Hospital, Taichung 40447, Taiwan
College of Medicine, China Medical University, Taichung 40402, Taiwan
Epigenome Research Center, China Medical University Hospital, Taichung 40447, Taiwan
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(6), 1586;
Received: 17 April 2018 / Revised: 17 May 2018 / Accepted: 22 May 2018 / Published: 28 May 2018
(This article belongs to the Collection Precision Medicine—From Bench to Bedside)
The nucleotide degrading enzyme gene RNASEH2A (ribonuclease H2 subunit A) has been found to be overexpressed in cancers. Our aim was to understand the role of RNASEH2A in cancer prognostication and to establish a scoring system based on the expressions of genes interacting with RNASEH2A. We screened the nucleotide degrading enzyme gene expression in RNAseq data of 14 cancer types derived from The Cancer Genome Atlas (TCGA) and found that RNASEH2A overexpression was associated with poor patient survival only in renal cell carcinomas (RCCs). Further cluster analyses of samples with poor outcomes revealed that cluster of differentiation 151 (CD151) upregulation correlated with low cyclin dependent kinase 1 (CDK1) and high RNASEH2A expression. The combination of low CD151 expression and high RNASEH2A expression resulted in impaired proliferation in four kidney cancer cell lines, suggesting potential synthetic dosage lethality (SDL) interactions between the two genes. A prognostication scoring system was established based on the expression levels of RNASEH2A-, CDK1-, and CD151-related genes, which could effectively predict the overall survival in a TCGA clear cell RCC cohort (n = 533, 995.3 versus 2242.2 days, p < 0.0001), in another clear cell renal cell carcinoma (ccRCC) cohort E-GEOD-22541 (n = 44, 390.0 versus 1889.2 days, p = 0.0007), and in a TCGA papillary RCC (pRCC) cohort (n = 287, 741.6 versus 1623.7 days, p < 0.0001). Our results provide a clinically applicable prognostication scoring system for renal cancers. View Full-Text
Keywords: RNASEH2A; CDK1; CD151; synthetic dosage lethality; renal cell carcinoma RNASEH2A; CDK1; CD151; synthetic dosage lethality; renal cell carcinoma
Show Figures

Figure 1

MDPI and ACS Style

Yang, C.-A.; Huang, H.-Y.; Yen, J.-C.; Chang, J.-G. Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers. Int. J. Mol. Sci. 2018, 19, 1586.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop